Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.45 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.41 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.38 |
| ▸ | GCGR | P47871 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10257184 | 0.93 | PPARG (0.47) | PPARGSERPINE1KMT2APTGESMCL1 | |
| SCHEMBL862434 | 0.91 | PPARG (0.48) | PPARGKMT2ACYP2C8MCL1MAPK8 | |
| SCHEMBL862037 | 0.91 | KMT2A (0.44) | PPARGKMT2ACYP2C8MCL1MAPK8 | |
| SCHEMBL10255644 | 0.91 | PPARG (0.46) | PPARGSCN5ASCN9AKMT2ACYP2C8 | |
| SCHEMBL862375 | 0.90 | KMT2A (0.44) | PPARGKMT2ACYP2C8MCL1MAPK8 | |
| SCHEMBL830979 | 0.90 | PPARG (0.41) | PPARGSCN9AKMT2ACYP2C8MCL1 | |
| SCHEMBL862122 | 0.89 | MAPK8 (0.42) | PPARGKMT2ACYP2C8MCL1MAPK8 | |
| SCHEMBL862622 | 0.89 | CYP2C8 (0.42) | PPARGKMT2ACYP2C8MCL1MAPK8 | |
| SCHEMBL862156 | 0.89 | KMT2A (0.42) | PPARGKMT2ACYP2C8MCL1MAPK8 | |
| SCHEMBL862357 | 0.89 | KMT2A (0.44) | PPARGKMT2APTGESCYP2C8MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | PPARG 4093/4885SERPINE1 3846/4885SCN5A 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.